查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830986

過動症治療市場

ADHD Therapeutics Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

2024 年，ADHD 治療市場價值約為 314.2 億美元，預計到 2031 年將成長至 662.7 億美元，2025 年至 2031 年的複合年成長率預計為 10.8%。

市場洞察與分析師觀點：注意力不足過動症 (ADHD) 是一種多方面的神經發育障礙，會影響個體集中注意力、控制衝動行為和控制過動症的能力。雖然此病主要在兒童期診斷，但症狀可能延續至青少年期和成年期。 ADHD 的治療通常採用綜合策略，包括行為療法、教育支持以及興奮劑和非興奮劑等藥物治療。

過動症（ADHD）盛行率的上升和治療藥物需求的增加是推動市場成長的關鍵因素。然而，ADHD藥物的副作用及其有限的療效對ADHD治療市場的擴張構成了挑戰。

成長因素與挑戰：根據美國疾病管制與預防中心（CDC）2022年2月發布的報告，2016年至2019年，美國約有600萬3至17歲兒童被診斷為ADHD，佔總人口的9.8%。此外，PubMed Central 2022年發表的一項研究表明，全球5%至7.2%的兒童和2.5%至6.7%的成年人患有ADHD。最近的估計表明，美國青少年的盛行率明顯更高，約為8.7%或530萬人。雖然傳統上ADHD被認為是一種兒童疾病，但近90%的ADHD兒童在成年後仍會持續出現症狀。此外，研究發現，75%的成年ADHD患者在兒童時期未被診斷出來。過動症 (ADHD) 常伴隨焦慮、憂鬱、學習障礙和藥物濫用等併發症，使治療更加複雜，需要採取綜合療法來應對 ADHD 症狀和相關疾病。建議使用精神興奮劑和非興奮劑等藥物來幫助兒童在日常生活中控制 ADHD 症狀，並規範可能影響其生活各個方面（包括人際關係和學業表現）的行為。因此，這些因素正在推動對 ADHD 藥物的需求，從而提升 ADHD 治療藥物的市場佔有率。

然而，由於症狀緩解效果有限且副作用較大，ADHD 治療市場的成長受到了阻礙。精神興奮劑的常見副作用包括食慾下降、失眠、焦慮加劇、易怒、胃痛和頭痛。此外，當藥物療效減弱時，ADHD 症狀可能會復發，導致“反彈”，甚至可能更加嚴重。

策略洞察報告細分和範圍：「ADHD 治療市場分析」是透過檢查以下細分進行的：藥物類型、年齡層和配銷通路。

分段分析：ADHD 治療市場依藥物類型分為興奮劑藥物和非興奮劑藥物。

2022 年，興奮劑類藥物佔據了 ADHD 治療市場的較大佔有率，預計 2022 年至 2030 年期間的複合年成長率將更高。

2022年及2030年ADHD治療市場（依藥物類型分類）依年齡層分類，ADHD治療市場分為兒童及青少年及成人兩大類。 2022年，兒童及青少年類藥物佔據了更大的市場佔有率，而成人類藥物預計在2022年至2030年期間將經歷更高的複合年成長率。

在分銷通路方面，ADHD治療市場分為醫院藥局、零售藥局和電商。 2022年，醫院藥房佔據了最大的市場佔有率，預計在2022年至2030年期間將實現最高的複合年成長率。

區域分析：ADHD 治療市場報告分析的主要地區包括北美、歐洲、亞太、南美和中美以及中東和非洲。

2022 年，北美佔據全球市場最大佔有率。在北美，美國在 2022 年佔據了最大的市場佔有率，預計在 2022 年至 2030 年期間仍將保持領先地位。 ADHD 治療市場的成長主要得益於美國 ADHD 的高盛行率。根據 Cingulate 的數據，2022 年約有 640 萬名 4 至 17 歲的兒童和青少年被診斷出患有 ADHD。其中，超過 80% 的人正在接受治療，約 65% 的人在成年後仍會繼續出現 ADHD 症狀。此外，患者負擔能力的提高、優惠的報銷政策以及對可用藥物的認知提高等因素預計將進一步推動市場成長。

亞太地區是過動症（ADHD）治療領域成長最快的市場，這得益於關鍵產業參與者的參與以及旨在開發和推廣新產品的各種策略性舉措。例如，2020年6月，大塚製藥株式會社和大塚製藥開發與商業化公司宣布了兩項為期六週的3期臨床試驗的積極成果，這些試驗評估了口服西他那法定（centanafadine）的有效性、安全性和耐受性。西他那法定是一種針對成人ADHD患者的新型實驗性藥物。該公司也計劃研究西他那法定對ADHD兒童的療效，並與美國食品藥物管理局（FDA）商討後續步驟。

產業發展與未來機會：ADHD治療市場的預測可以幫助利害關係人制定成長策略。市場主要參與者採取的關鍵措施包括：

2023年9月，Cingulate Inc. 發表了其主要候選藥物 CTx-1301（右哌甲酯）用於治療成人多動症的有效性和安全性的3期臨床研究結果。該公司採用其專利的精準定時釋放 (PTR) 藥物遞送平台技術，開發一系列下一代醫藥產品。研究結果於 9 月 8 日在田納西州納許維爾舉行的第 36 屆年度心理學大會上發表。 2022 年 3 月，久光製藥株式會社的全資子公司 Noven Pharmaceuticals, Inc. 的 XELSTRYM（右旋安非他明）透皮系統 CII 獲得美國食品藥物管理局 (FDA) 批准，用於治療成人和 6 歲及以上兒童患者的 ADHD。 2021 年 7 月，Corium, Inc. 在美國推出了 AZSTARYS，這是一種結合了舍曲林 (SDX) 和右旋哌甲酯 (d-MPH) 的創新藥物，用於 6 歲及以上患者的症狀治療。 AZSTARYS 於 2021 年 3 月獲得 FDA 批准，由兩種藥物組合組成：70% 緩釋 d-MPH SDX 前藥（附表 IV）和 30% 速釋 d-MPH（附表 II）。 2021 年 4 月，Supernus Pharmaceuticals, Inc. 宣布美國 FDA 已批准 Qelbree（維洛沙嗪緩釋膠囊）用於治療 6 至 17 歲患者的 ADHD。競爭格局和主要公司：ADHD 治療市場報告中介紹的主要參與者包括 Amneal Pharmaceuticals, Inc.；諾華公司；輝瑞公司；禮來公司；Noven Pharmaceuticals, Inc.；楊森製藥公司；強生服務公司；Corium Inc；Adlon Therapeutics LP；和 Teva Pharmaceutical Industries Ltd.。這些公司實施產品開發策略以滿足客戶日益成長的需求，使他們能夠維持品牌聲譽。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：ADHD治療市場格局

  • 概述
  • PEST分析
  • 生態系分析
    • 價值鏈中的供應商列表

第5章：注意力不足過動症（ADHD）治療市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：注意力不足過動症治療市場－全球市場分析

  • ADHD 治療 - 全球市場概覽
  • ADHD 治療 - 全球市場及 2030 年預測

第 7 章：注意力不足過動症 (ADHD) 治療市場 - 收入分析 - 按藥物類型，2020-2030 年

  • 概述
  • 興奮劑
  • 非興奮劑

第 8 章：注意力不足過動症 (ADHD) 治療市場 - 收入分析 - 按年齡層，2020-2030 年

  • 概述
  • 兒童和青少年
  • 成年人

第 9 章：注意力不足過動症 (ADHD) 治療市場 - 收入分析 - 按配銷通路，2020-2030 年

  • 概述
  • 醫院藥房
  • 零售藥局
  • 電子商務

第 10 章：ADHD 治療市場 - 收入分析，2020-2030 年 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 12 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 13 章：注意力不足過動症 (ADHD) 治療市場 - 主要公司簡介

  • Amneal Pharmaceuticals, Inc
  • Novartis AG
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Noven Pharmaceuticals, Inc.
  • Janssen Pharmaceuticals, Inc
  • Johnson and Johnson Services, Inc.
  • Corium Inc
  • Adlon Therapeutics L.P
  • Teva Pharmaceutical Industries Ltd

第 14 章：附錄

簡介目錄
Product Code: TIPRE00003833

The ADHD therapeutics market was valued at approximately US$ 31.42 billion in 2024 and is projected to grow to US$ 66.27 billion by 2031, with an estimated CAGR of 10.8% from 2025 to 2031.

Market Insights and Analyst Perspective:Attention deficit/hyperactivity disorder (ADHD) is a multifaceted neurodevelopmental disorder that impacts an individual's capacity to concentrate, manage impulsive actions, and control hyperactivity. While it is primarily diagnosed in childhood, symptoms can extend into adolescence and adulthood. Treatment for ADHD typically employs a comprehensive strategy that includes behavioral therapy, educational support, and medications such as stimulants and non-stimulants.

The increasing prevalence of ADHD and the rising demand for therapeutic drugs are key factors driving market growth. However, the side effects linked to ADHD medications and their limited effectiveness pose challenges to the expansion of the ADHD therapeutics market.

Growth Factors and Challenges:According to a report from the Centers for Disease Control and Prevention (CDC) published in February 2022, around 6 million children aged 3 to 17 in the US were diagnosed with ADHD, representing 9.8% of the population from 2016 to 2019. Furthermore, a study published by PubMed Central in 2022 indicated that ADHD affects 5 to 7.2% of children and 2.5 to 6.7% of adults globally. Recent estimates suggest that the prevalence among adolescents in the US is significantly higher, at about 8.7% or 5.3 million. Although ADHD has been traditionally viewed as a childhood disorder, nearly 90% of children with ADHD continue to exhibit symptoms into adulthood. Additionally, 75% of adults with ADHD were not diagnosed during childhood, as per research findings. ADHD is often accompanied by comorbid conditions such as anxiety, depression, learning disabilities, and substance abuse, complicating treatment and necessitating a comprehensive approach that addresses both ADHD symptoms and these associated conditions. Medications like psychostimulants and non-stimulants are recommended to help children manage their ADHD symptoms in daily life and regulate behaviors that may disrupt various aspects of their lives, including personal relationships and academic performance. Consequently, these factors are driving the demand for ADHD medications, thereby enhancing the market share of ADHD therapeutics.

Nonetheless, the growth of the ADHD therapeutics market is hindered by the limited symptom relief and the side effects associated with these treatments. Common side effects of psychostimulant medications include reduced appetite, insomnia, heightened anxiety, increased irritability, stomach pain, and headaches. Additionally, when the medication's effects diminish, ADHD symptoms may re-emerge, leading to a "rebound" effect that can be more severe.

Strategic Insights

Report Segmentation and Scope:The "ADHD therapeutics market analysis" has been conducted by examining the following segments: drug type, age group, and distribution channel.

Segmental Analysis:The ADHD therapeutics market is categorized by drug type into stimulants and non-stimulant medications.

The stimulant drug segment accounted for a larger share of the ADHD therapeutics market in 2022 and is expected to exhibit a higher CAGR from 2022 to 2030.

ADHD Therapeutics Market by Drug Type - 2022 and 2030By age group, the ADHD therapeutics market is divided into pediatric & adolescent and adult segments. The pediatric & adolescent segment held a larger market share in 2022, while the adult segment is projected to experience a higher CAGR from 2022 to 2030.

Regarding distribution channels, the ADHD therapeutics market is segmented into hospital pharmacies, retail pharmacies, and E-commerce. In 2022, the hospital pharmacies segment captured the largest market share and is expected to achieve the highest CAGR during the period from 2022 to 2030.

Regional Analysis:The major regions analyzed for the ADHD therapeutics market report include North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

In 2022, North America held the largest share of the global market. Within North America, the US accounted for the largest market share in 2022 and is projected to maintain its leading position from 2022 to 2030. The growth of the ADHD therapeutics market is significantly driven by the high prevalence of ADHD in the US. According to Cingulate, approximately 6.4 million children and adolescents aged 4 to 17 were diagnosed with ADHD in 2022. Of this group, over 80% are receiving treatment, and about 65% continue to experience ADHD symptoms into adulthood. Additionally, factors such as improved patient affordability, favorable reimbursement policies, and heightened awareness of available medications are expected to further propel market growth.

Asia Pacific is the fastest-growing market for ADHD, attributed to the presence of key industry players and various strategic initiatives aimed at developing and marketing new products. For instance, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. announced positive outcomes from two six-week phase 3 clinical trials evaluating the effectiveness, safety, and tolerability of oral centanafadine, a new experimental drug intended for adult patients diagnosed with ADHD. The company also plans to investigate the effects of centanafadine in children with ADHD and discuss subsequent steps with the US Food and Drug Administration.

Industry Developments and Future Opportunities:The forecast for the ADHD therapeutics market can assist stakeholders in formulating their growth strategies. Key initiatives undertaken by major players in the market include:

In September 2023, Cingulate Inc. reported results from its Phase 3 study on the efficacy and safety of its lead candidate, CTx-1301 (dexmethylphenidate), for treating ADHD in adults. The company employs its patented Precision Timed Release (PTR) drug delivery platform technology to develop a pipeline of next-generation pharmaceutical products. The results were presented on September 8th at the 36th Annual Psych Congress in Nashville, TN.

In March 2022, Noven Pharmaceuticals, Inc., a wholly owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., received approval from the US Food and Drug Administration (FDA) for its XELSTRYM (dextroamphetamine) transdermal system, CII, for the treatment of ADHD in adults and pediatric patients aged six years and older.

In July 2021, Corium, Inc. launched AZSTARYS, an innovative medication that combines Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) in the US for the symptomatic treatment of patients aged 6 years and older. AZSTARYS received FDA approval in March 2021 and consists of a combination of two types of medication: 70% extended-release prodrug of d-MPH SDX (Schedule IV) and 30% immediate-release d-MPH (Schedule II).

In April 2021, Supernus Pharmaceuticals, Inc. announced that the US FDA had approved Qelbree (viloxazine extended-release capsules) for the treatment of ADHD in patients aged 6 to 17.

Competitive Landscape and Key Companies:Key players profiled in the ADHD therapeutics market report include Amneal Pharmaceuticals, Inc.; Novartis AG; Pfizer, Inc.; Eli Lilly and Company; Noven Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Services, Inc.; Corium Inc; Adlon Therapeutics LP; and Teva Pharmaceutical Industries Ltd. These companies implement product development strategies to meet the increasing demands of customers, enabling them to sustain their brand reputation.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. ADHD Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. ADHD Therapeutics Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. ADHD Therapeutics Market - Global Market Analysis

  • 6.1 ADHD Therapeutics - Global Market Overview
  • 6.2 ADHD Therapeutics - Global Market and Forecast to 2030

7. ADHD Therapeutics Market - Revenue Analysis (USD Million) - By Drug Type, 2020-2030

  • 7.1 Overview
  • 7.2 Stimulants
  • 7.3 Non-Stimulants

8. ADHD Therapeutics Market - Revenue Analysis (USD Million) - By Age Group, 2020-2030

  • 8.1 Overview
  • 8.2 Pediatric and Adolescent
  • 8.3 Adults

9. ADHD Therapeutics Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 E-Commerce

10. ADHD Therapeutics Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America ADHD Therapeutics Market Overview
    • 10.1.2 North America ADHD Therapeutics Market Revenue and Forecasts to 2030
    • 10.1.3 North America ADHD Therapeutics Market Revenue and Forecasts and Analysis - By Drug Type
    • 10.1.4 North America ADHD Therapeutics Market Revenue and Forecasts and Analysis - By Age Group
    • 10.1.5 North America ADHD Therapeutics Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 10.1.6 North America ADHD Therapeutics Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States ADHD Therapeutics Market
        • 10.1.6.1.1 United States ADHD Therapeutics Market, by Drug Type
        • 10.1.6.1.2 United States ADHD Therapeutics Market, by Age Group
        • 10.1.6.1.3 United States ADHD Therapeutics Market, by Distribution Channel
      • 10.1.6.2 Canada ADHD Therapeutics Market
        • 10.1.6.2.1 Canada ADHD Therapeutics Market, by Drug Type
        • 10.1.6.2.2 Canada ADHD Therapeutics Market, by Age Group
        • 10.1.6.2.3 Canada ADHD Therapeutics Market, by Distribution Channel
      • 10.1.6.3 Mexico ADHD Therapeutics Market
        • 10.1.6.3.1 Mexico ADHD Therapeutics Market, by Drug Type
        • 10.1.6.3.2 Mexico ADHD Therapeutics Market, by Age Group
        • 10.1.6.3.3 Mexico ADHD Therapeutics Market, by Distribution Channel
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. ADHD Therapeutics Market - Key Company Profiles

  • 13.1 Amneal Pharmaceuticals, Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Novartis AG
  • 13.3 Pfizer, Inc.
  • 13.4 Eli Lilly and Company
  • 13.5 Noven Pharmaceuticals, Inc.
  • 13.6 Janssen Pharmaceuticals, Inc
  • 13.7 Johnson and Johnson Services, Inc.
  • 13.8 Corium Inc
  • 13.9 Adlon Therapeutics L.P
  • 13.10 Teva Pharmaceutical Industries Ltd

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud